Loading data for AVBP — first visit, this takes a few seconds.

Alert

ArriVent BioPharma Inc. (AVBP)

NasdaqGM: AVBP · Real-Time Price · USD

29.91

-0.09 (-0.30%)

At close: Aug 19, 2026, 6:32 PM

-0.30% (1D)

No data available

Bid	22.54
Market Cap	1.46B
Revenue (ttm)	n/a
Net Income (ttm)	-164.21M
Beta	1.37
EPS (ttm)	-3.55
PE Ratio (ttm)	n/a
Forward PE	-7.8
P/B (ttm)	3.91
P/S (ttm)	n/a
Earnings Date	Aug 14, 2026

Ask	38.95
Volume	243,740
Avg. Volume (20D)	565,579
Open	29.99
Previous Close	30.00
Day's Range	29.13 - 30.07
52-Week Range	17.00 - 35.83
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About AVBP

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2024

Employees 77

Stock Exchange NasdaqGM

Ticker Symbol AVBP

Website https://arrivent.com

Full Company Profile

Financial Performance

In 2025, ArriVent BioPharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -166.31M, an increase of 106.62%.

Financial Statements

Earnings Surprise

ArriVent BioPharma has released their quarterly earnings on May 11, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.96 misses estimates by -0.07, with 49.47% YoY growth.

Next Earnings Release

ArriVent BioPharma Inc. is scheduled to release its earnings on Aug 14, 2026, after market closes.
Analysts project revenue of ... Upgrade

News

3 months ago · Simply Wall St.

A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate

ArriVent BioPharma (AVBP) stock is in focus after the FDA cleared its investigational new drug application for ARR-002, a dual-target antibody drug conjugate for ovarian and endometrial cancers. See o...

4 months ago · Zacks

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago · Zacks

Are Medical Stocks Lagging AstraZeneca (AZN) This Year?

Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.

4 months ago · Zacks

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

4 months ago · Simply Wall St.

Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest

Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted c...

Page 1 of 2

ArriVent BioPharma Inc. (AVBP)